Jazz Pharmaceuticals PLC
JAZZ
ISIN IE00B4Q5ZN47 / Valor 14769757
Jazz Pharmaceuticals PLC
UMushroom community rating:
About company
Jazz Pharmaceuticals PLC is a biopharmaceutical company known for its focus on developing and commercializing innovative medicines aimed at addressing significant unmet medical needs. With a strong presence on the NASDAQ (JAZZ), the company has carved out a niche in the healthcare sector, particularly in the areas of sleep disorders, epilepsy, and oncology. Jazz Pharmaceuticals boasts a diverse portfolio of marketed medicines, with leading therapies that have made substantial impacts in their respective fields. The company's commitment to patient-focused and science-driven initiatives is evident in its robust pipeline, which is dedicated to pioneering research and development in oncology and neuroscience. Through its efforts, Jazz Pharmaceuticals aims to transform the lives of patients and their families by offering new, advanced therapeutic options.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (16.11.2025):
Jazz Pharmaceuticals PLC delivered impressive Third Quarter 2025 financial results, achieving the highest revenue quarter in its history. The company’s diversified portfolio, including strong performances from Epidiolex, Xywav, and the newly launched Modeyso, drove a 7% increase in total revenues year-over-year. Key oncology and neuroscience products, combined with significant FDA approvals and strategic product launches, have reinforced its market position and led to an updated 2025 financial guidance.
Record Revenue Growth
Total revenues for 3Q25 reached $1,126,107 thousand, up 7% compared to 3Q24, with robust contributions from double‐digit growth drivers such as Epidiolex and Xywav. This milestone marks the highest revenue quarter in Jazz Pharmaceuticals PLC’s history.
New Product Launches and FDA Approvals
3Q25 witnessed noteworthy advancements including the commercial launch of Modeyso in August 2025, which achieved $11.0 million in sales, and FDA approval of the Zepzelca® and atezolizumab combination for 1L ES-SCLC maintenance therapy. These approvals and launches underline the company’s commitment to expanding its treatment portfolio across critical therapeutic areas.
Financial Performance and Expense Dynamics
Improved GAAP net income of $251,412 thousand (up from $215,055 thousand in 3Q24) reflects strong operational execution. However, increased SG&A expenses—driven by significant litigation settlements—and changes in product cost mix impacted margins, while R&D expenses showed a decrease due to timing variances in clinical trials and integration costs.
Guidance and Strategic Updates
Jazz Pharmaceuticals PLC narrowed its 2025 total revenue guidance range to $4.175–$4.275 billion from $4.150–$4.300 billion, reflecting strengthened confidence in sustained revenue growth. Additionally, strategic corporate moves, such as the appointment of Dr. Ted Love to the Board and a global licensing agreement with Saniona, further position the company for future innovations and market expansion.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
10336 M
Market cap (USD)
6,719,133
Daily traded volume (Shares)
124.03 / 122.1
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Eric Strauss
Lea Katunaric
Luba Schoenig
EQUITIES OF THE SAME SECTOR
